Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celadon Pharmaceuticals PLC (GB:CEL)
LSE:CEL
Holding GB:CEL?
Track your performance easily
CEL Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range11.00p - 122.50p
Previous Close15p
Volume45.84K
Average Volume (3M)92.43K
Market Cap
£10.33M
Enterprise Value5.37M
Total Cash (Recent Filing)£9.08M
Total Debt (Recent Filing)£4.59M
Price to Earnings (P/E)―
Beta-1.77
Next Earnings
Apr 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding66,220,807
10 Day Avg. Volume40,408
30 Day Avg. Volume92,430
Standard Deviation0.44
R-Squared0.00063
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)300.00
Price to Sales (P/S)1241.64
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Celadon Pharmaceuticals PLC News
PremiumCompany Announcements
Celadon Pharmaceuticals Strengthens Financial Footing
PremiumCompany Announcements
Celadon Pharmaceuticals Faces Financial Uncertainties
PremiumCompany Announcements
Celadon Pharmaceuticals Hosts Shareholder Facility Tour
PremiumCompany Announcements
Celadon Pharmaceuticals Secures Lucrative Cannabis Contract
PremiumCompany Announcements
Celadon Pharmaceuticals Announces CFO Departure
PremiumCompany Announcements
Celadon Pharmaceuticals Advances Despite Funding Delays
PremiumCompany Announcements
Celadon Pharmaceuticals Expands Share CapitalCEL FAQ
What was Celadon Pharmaceuticals PLC’s price range in the past 12 months?
Celadon Pharmaceuticals PLC lowest share price was 11.00p and its highest was 122.50p in the past 12 months.
What is Celadon Pharmaceuticals PLC’s market cap?
Currently, no data Available
When is Celadon Pharmaceuticals PLC’s upcoming earnings report date?
Celadon Pharmaceuticals PLC’s upcoming earnings report date is Apr 25, 2025 which is in 123 days.
How were Celadon Pharmaceuticals PLC’s earnings last quarter?
Celadon Pharmaceuticals PLC released its earnings results on Sep 30, 2024. The company reported -0.037p earnings per share for the quarter, missing the consensus estimate of N/A by -0.037p.
Is Celadon Pharmaceuticals PLC overvalued?
According to Wall Street analysts Celadon Pharmaceuticals PLC’s price is currently Overvalued.
Does Celadon Pharmaceuticals PLC pay dividends?
Celadon Pharmaceuticals PLC does not currently pay dividends.
What is Celadon Pharmaceuticals PLC’s EPS estimate?
Celadon Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celadon Pharmaceuticals PLC have?
Celadon Pharmaceuticals PLC has 68,845,810 shares outstanding.
What happened to Celadon Pharmaceuticals PLC’s price movement after its last earnings report?
Celadon Pharmaceuticals PLC reported an EPS of -0.037p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -24.658%.
Which hedge fund is a major shareholder of Celadon Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:CEL
---
Celadon Pharmaceuticals PLC Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.95%
12-Months-Change
Fundamentals
Return on Equity
-192.32%
Trailing 12-Months
Asset Growth
-10.55%
Trailing 12-Months
Company Description
Celadon Pharmaceuticals PLC
Summerway Capital PLC operates as an investment holding company. It is focused on acquiring businesses that are either headquartered in the UK or that have substantial operations in the UK. The company is principally focused on opportunities in the wider household and consumer goods sector, including retail and consumer brands, particularly where there is an opportunity to introduce operational and performance improvements, including new technologies and associated operating and value leverage.
---
Technical Analysis
---